NasdaqGS:ORICBiotechs
A Look at ORIC Pharmaceuticals (ORIC)'s Valuation Following New ORIC-944 Preclinical Data Release
ORIC Pharmaceuticals (ORIC) unveiled new preclinical data for its investigational drug ORIC-944 at the 2025 EORTC-NCI-AACR International Conference. The announcement focused on the drug's impact in prostate cancer and other solid tumors.
See our latest analysis for ORIC Pharmaceuticals.
ORIC Pharmaceuticals has seen a wave of interest following its latest clinical update, with the share price up 53.6% year-to-date and a 33.9% total shareholder return in the past year. Positive momentum has...